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Dynamic contrast imaging techniques are considered the standard of care for the radiolog-
ical diagnosis of hepatocellular carcinoma (HCC) in cirrhosis. However, the accuracy of
radiological diagnosis depends largely on the degree of arterial hypervascularization,
which increases with tumor size. Owing to the interplay and prognostic relevance of tumor
vascularization and cell differentation, we asked ourselves whether tumor grade also affects
the outcome of radiological diagnosis. Sixty-two HCCs (47 of which measured 1-2 cm)
were consecutively detected in 59 patients with compensated cirrhosis under surveillance
with ultrasound and conﬁrmed by way of echo-guided biopsy and concurrent investiga-
tions with contrast-enhanced ultrasound (CE-US), computed tomography (CT), and gad-
olinium magnetic resonance imaging (MRI). Tumor cell differentiation was evaluated
using Edmondson-Steiner criteria in liver cores of 0.9-5.0 cm (median 1.6 cm). Eighteen
(29%) HCCs were grade I (1.5 cm), 28 (45%) were grade II (1.5 cm), 16 (26%) were grade
III (1.8 cm), and none were grade IV. Contrast wash-in and wash-out were concurrently
demonstrated in 21 (34%) tumors by way of CE-US, including three (16%) grade I and 18
(41%) grade II-III (P 5 0.08); in 32 (52%) tumors by way of CT, including three (16%)
grade I and 29 (66%) grade II-III (P 5 0.0006); and 28 (47%) tumors by way of MRI,
including three grade I (16%) and 25 (57%) grade II-III (P 5 0.01). Among 1- to 2-cm
tumors, the radiological diagnosis was achieved in two of 16 grade I and 17of 31 grade
II-III tumors (P 5 0.006). Conclusion: Tumor grade, a relevant predictor of disease
severity, inﬂuences the accuracy of dynamic contrast techniques in the diagnosis of HCC.
(HEPATOLOGY 2010;52:1723-1730)
S
urveillance with abdominal ultrasound (US) of
patients with cirrhosis, who are at risk of hepato-
cellular carcinoma (HCC), is the standard of
care to detect small, potentially curable tumors.1 A
standardized recall policy for liver nodules detected on
US examination has been established that uses
dynamic contrast imaging techniques to show the pa-
thognomonic pattern of contrast wash-in in the arterial
phase followed by wash-out in the venous phase. Nod-
ules that escape radiological diagnosis can be investi-
gated using echo-guided liver biopsy and/or as
enhanced follow-up with imaging.2 Whereas two con-
trast imaging techniques with concordant wash-in/
wash-out patterns are required for the diagnosis of 2
cm tumors, contrast-enhanced US (CE-US), spiral
computed tomography (CT), or dynamic magnetic
resonance imaging (MRI) alone sufﬁces to diagnose
>2 cm nodules.2,3 In a validation study performed by
Forner and colleagues,4 the concurrent application of
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CE-US and gadolinium MRI showed 33.3% sensitivity
and 100% speciﬁcity for the diagnosis of 0.5- to 2-cm
HCCs using histology with ﬁne-needle biopsy (FNB)
as a diagnostic gold standard. In that study, CE-US
was combined with gadolinium MRI, because previous
investigations by the same group in explanted livers
showed better diagnostic performance of MRI than
CT scan in the identiﬁcation of small HCC nodules.5
Recently, the accuracy of CE-US has been questioned
owing to a discrete number of false positive diagnoses
of HCC in patients with an intrahepatic cholangio-
carcinoma, a tumor that is increasingly seen in
patients with HCV-related cirrhosis and, at variance
with HCC, is a contraindication for orthotopic liver
transplantation.6,7
Because HCC growth depends not only on the rate
of arterial vascularization, which accounts for the pa-
thognomonic pattern of HCC on contrast imaging,
but also on tumor grade,8 we wondered whether the
diagnostic accuracy of dynamic contrast imaging tech-
niques could be inﬂuenced by the degree of tumor cell
differentiation, as well. To address this question, we
assessed tumor grade in the liver cores of de novo
HCC nodules that were consecutively diagnosed in 59
patients with compensated cirrhosis who were under
surveillance and were concurrently examined with CE-
US, dynamic gadolinium MRI, and contrast CT.
Patients and Methods
This study was a subanalysis of a previous inde-
pendent, investigator-driven, prospective study aimed
to compare the accuracy of CE-US, CT, and MRI in
the diagnosis of de novo HCC nodules in patients
with compensated cirrhosis who were under surveil-
lance with US.9
Between April 2006 and December 2009, all
patients with Child-Pugh class A or B cirrhosis with a
de novo liver nodule detected during surveillance were
investigated consecutively. Excluded were patients with
a pre-existing liver nodule, poor liver function (Child-
Pugh C) indicating liver transplantation independently
on HCC, or an echo-coarse US pattern of the liver
without a well-deﬁned liver nodule. After giving
informed consent, patients underwent a detailed medi-
cal history, physical examination, and complete blood
count and biochemical tests, including serum alpha-
fetoprotein (AFP; normal,  20 ng/mL) (IRMA;
Abbott, North Chicago, IL) and markers for viral hep-
atitis and autoimmunity. In all patients, abdominal
CT, MRI, and CE-US examinations and a US-guided
FNB were performed within 2 months of detection of
a liver nodule.
Histology of Liver Nodules. The diagnostic refer-
ence standard was histology. In each patient, an FNB
was concurrently performed within the nodule and the
surrounding liver parenchyma. The procedure was
repeated in all cases with unsolved histological diagno-
sis (i.e., patients showing similar histological features
of cirrhosis within and outside the nodule). A 21-
gauge trenchant needle for microhistology (Biomol,
HS Hospital Service, Italy) was used, and the diagnosis
was made according to International Working Party
criteria.10 Formalin-ﬁxed,parafﬁn-embedded liver sec-
tions were examined by an experienced liver patholo-
gist (G. R.) who was unaware of the results of the
clinical and radiological examinations. All liver biopsy
samples were re-evaluated by a second expert patholo-
gist (M. R.) who was unware of the clinical, radiologi-
cal, and pathological diagnoses. The criteria for diag-
nosing small and well-differentiated HCCs, which
include the so-called very early HCC, are well standar-
dized.11,12 Table 1 shows the criteria used to distin-
guish well-differentiated HCCs from high-grade dys-
plastic nodules. Tumor cell differentiation was
evaluated according to the Edmondson-Steiner grading
system.13 Figure 1 shows the representative histological
features of HCC grading of the series under study.
Vascular Pattern of HCC. Arterial hypervasculariza-
tion (contrast wash-in) was a contrast hyperenhance-
ment of the nodule (hyperechogenicity on US, hyper-
density on CT, hyperintensity on MRI) taking place
during the arterial phase of the radiological examina-
tion, as compared with the surrounding liver paren-
chyma. Portal/venous contrast wash-out was a hypoen-
hanced pattern of the nodule (hypoechogenicity on
US, hypodensity on CT, hypointensity on MRI) with
respect to the surrounding liver parenchyma taking
place during the portal/venous phase of the radiologi-
cal examination. The typical radiological pattern of
Table 1. Main Criteria to Distinguish Well-Differentiated HCC
from High-Grade Dysplastic Nodules
Features
High-Grade
Dysplastic Nodules
Well-Differentiated
HCC
Thickness of plates Up to 2 >2*
Cell crowding 1.5-2 >2*
Uniformly increased N/C ratio** No Yes
Irregular thin trabecular pattern No Yes
Frequent acinar arrangement No Yes
Diffuse steatosis Rare Frequent
Stromal invasion Never detectable May be detectable
Reticulin framework decrease/loss Never detectable May be detectable
Nodule in nodule growth pattern Never detectable May be detectable
*Compared with surroundings.
**Nucleus to cytoplasmic ratio.
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HCC was the presence of wash-in followed by wash-
out of the contrast medium. According to the Ameri-
can Association for the Study of the Liver Disease
guidelines, the radiological diagnosis of HCC in 1- to
2-cm HCC was the presence of the typical radiological
pattern on two dynamic imaging techniques. For >2-
cm nodules, a single dynamic study showing the typi-
cal vascular pattern for HCC is required.2 CT and
MRI images were blindly and independently read by
two experienced radiologists (L. V. F. and P. B.) who
were unaware of the liver biopsy results.
MRI. MRI was performed with a 1.5-T system
(Avanto; Siemens Medical Systems, Erlangen, Ger-
many) using a phased-array torso coil for signal detec-
tion. All patients underwent transverse T1-weighted
and T2-weighted MRI and multiphasic contrast-
enhanced dynamic three-dimensional MRI of the
whole liver with fat suppression. T1-weighted imaging
included breath-hold in-phase gradient echo (175/5
TR/TE, 256  112 matrix, 70 ﬂip angle) and out-
of-phase gradient echo (175/2.38 TR/TE, 256 112
matrix, 70 ﬂip angle). T2-weighted imaging included
fat suppression sequences (1310/70 TR/TE, 320 
192 matrix). Dynamic MRI was performed with a
three-dimensional volumetric interpolated breath-hold
examination sequence in an axial plane using the fol-
lowing parameters: 4.7/2.3 TR/TE, 320  157 matrix,
10 ﬂip angle, 3-mm slice thickness. Gadolinium
(Gadobenate Dimeglutamine [0.5 mmol/L]; Multi-
hance, Bracco, Milan, Italy) was injected at a dose of
0.2 mL/kg at a rate of 2 mL/second. Arterial phase,
portal venous, and delayed venous phase images were
acquired approximately 30, 80, and 180 seconds from
the start of contrast injection, respectively. A breath-
hold T1-weighted two-dimensional gradient echo with
fat suppression MRI (4.7/2.3 TR/TE, 256  157 ma-
trix) and three-dimensional volumetric interpolated
breath-hold examination sequences were performed 2
hours after contrast injection (hepatocyte phase).
CT. CT was performed with a 64-detector CT scan-
ner (Deﬁnition Siemens, Erlangen, Germany) at 2.5-
mm slice thickness and a rotation time of 0.5 seconds.
A total of 1.5 mg/kg iodinated contrast medium
(Iomeron 400; Bracco, Milan, Italy) was injected with
Fig. 1. Representative histological features of HCC grading. (A) Grade I microtrabecular tumor with uniformly small, regular neoplastic hepato-
cytes (10, inset magniﬁcation 40). (B) Grade II pseudoglandular tumor with malignant hepatocytes displaying irregular nuclear contours and
nucleoli (25, inset magniﬁcation 40). (C) Grade III solid tumor with more pleomorphic cells (25, inset magniﬁcation 40). (D) High mag-
niﬁcation of a grade IV tumor showing more anaplastic changes (archived specimen; 10, inset magniﬁcation 40).
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a 4.0 mL/second ﬂow. In all patients, the acquisition
time from the start of contrast injection and the start
of acquisition sequences was 40 seconds for the arterial
phase, 80 seconds for the portal venous phase, and
180 seconds for the delayed phase. Patients with an
unsatisfactory acquisition of arterial phase were to
repeat the examination using a bolus tracking
technique.
CE-US. US studies were performed with a Philips
iU22 system (Philips Ultrasound, Bothell, WA), using
a multifrequency (5-2 MHz) convex transducer (C5-
2). A preliminary gray-scale US examination of the
upper abdomen was performed. On identifying the
nodule, CE-US was performed with up to two bolus
injections of 2.4 mL of a second-generation contrast
agent (SonoVue; Bracco, Milan, Italy), having 8-lm
microbubbles and stability for 6-8 minutes. The bolus
was followed by a 10-mL saline ﬂush. Low mechanical
index (<0.1) was set for CE-US examination.
Enhancement patterns were studied during the vascular
phase for up to 3 minutes, including the arterial phase
(0-35 seconds), portal phase (35-120 seconds), and
late phase (120-180 seconds). All examinations were
obtained and evaluated in real time by two expert
echographists (M. F. and S. M.) and digitally stored
and documented by a commercially available system or
videotapes. Patients with a discrepant result were re-
evaluated in a dedicated reading session by the two
echographists, who were unaware of the liver biopsy
results.
Statistical Analysis. The baseline characteristics of
the patients are expressed as the median and range or
count and proportion. Comparisons between the vas-
cular pattern and tumor cell differentiation of the nod-
ules were performed using a Student t test or Mann-
Whitney test for continuous variables and Fisher’s
exact test for categorical variables. A conventional P
value < 0.05 was considered statistically signiﬁcant.
Calculations were performed with the Stata version
10.0 statistical package (Stata 1944-2007, College Sta-
tion, TX).
Results
Sixty-two HCC nodules were detected consecutively
in 59 patients with cirrhosis who were under surveil-
lance with US (Table 2). The diagnosis of HCC was
histologically conﬁrmed in liver biopsy cores ranging
from 0.9 to 5.0 cm (median 1.6 cm). To assess intra-
assay variation, 18 tumors (29%) were sampled twice
during the same session, and the cores were blindly
assessed for tumor cell differentiation by the same pa-
thologist. Thirteen (72%) tumors yielded concordant
readings (mean size 1.8 cm, weighted K 0.615),
whereas in the ﬁve nodules with discordant results
(mean size 1.8 cm), the worst grading was considered.
Only one of the ﬁve discordant HCCs was a grade I
versus grade II tumor, whereas the remaining four
nodules were discordant for grade II versus grade III.
Table 2. Demography of the 59 Patients with Compensated
Cirrhosis and a De Novo HCC Nodule
Male sex 41 (69)
Age, years 66 (44-85)
HCV-RNA 42 (71)
HBsAg 7 (12)
Alcohol 4 (7)
Other risk factors 6 (10)
HCC size
0.5-1 cm 3 (5)
1-2 cm 47 (76)
2-3 cm 12 (19)
Data are presented as n (%) or median (range).
Abbreviations: HBsAg hepatitis B surface antigen; HCV, hepatitis C virus.
Table 3. Patient Characteristics Stratiﬁed According to Tumor Cell Grading (No Grade IV Tumors)
Characteristics Grade I Grade II-III P Value
HCC nodule 18 (29%) 44 (71%) —
Male sex 12 (66%) 32 (73%) 0.75
Age, years 70 (52-83) 64 (44-85) 0.04
HCV etiology 15 (83%) 30 (68%) 0.35
Child-Pugh class A 17 (94%) 42 (95%) 1.0
Serum AFP, ng/mL 8 (1-353) 14 (2-2156) 0.6
Nodule size, cm 1.5 (1.1-2.5) 1.6 (0.8-3.0) 0.6
0.5-1 cm 0 3 0.26
1-2 cm 16 31 —
>2 cm 2 10 —
Typical vascular pattern on CE-US 3 (17%) 18 (41%) 0.08
Typical vascular pattern on CT 3 (17%) 29 (66%) 0.0006
Typical vascular pattern on MRI 4 (22%) 25 (57%) 0.01
Data are presented as n (%) or median (range).
Abbreviations: HCV, hepatitis C virus.
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There were 18 (29%) grade I tumors with a median
size of 1.5 cm (range 1.1-2.5 cm), 28 (45%) grade II
tumors with a median size of 1.5 (range 1.0-3.0 cm),
16 (26%) grade III tumors with a median size of 1.8
(range 1.0-2.6 cm), and no grade IV tumors. Of the
47 tumors measuring 1-2 cm in size, 16 (34%) were
grade I, 20 (43%) were grade II, and 11 (23%) were
grade III. Table 3 shows the correlation between the
results of contrast imaging techniques and tumor cell
grading. CE-US yielded a combined pattern of con-
trast wash-in and wash-out in three (17%) grade I and
18 (41%) grade II-III tumors (P ¼ 0.08). CT yielded
the typical vascular pattern in three (17%) grade I and
29 (66%) grade II-III nodules (P ¼ 0.0006). Finally,
MRI gave the typical vascular pattern in four (25%)
grade I and 25 (57%) grade II-III nodules (P ¼ 0.01).
The distribution of tumor cell grading was similar
according to patient age, disease etiology, serum levels
of liver enzymes, tumor size, and serum AFP values
(Table 3). Table 4 shows the correlation between the
results of contrast imaging techniques and tumor size.
Of the 1- to 2-cm nodules showing two coincidental
results by contrast imaging techniques, a radiological
diagnosis was obtained in two of 12 (17%) grade I
tumors and 17 of 31 (55%) grade II-III tumors (P ¼
0.006) (Table 5). Multivariate analysis revealed that tu-
mor cell dedifferentiation (odds ratio 12.38; 95% con-
ﬁdence interval 2.39-64.13; P ¼ 0.003) and tumor
size (odds ratio 3.73; 95% conﬁdence interval 1.15-
12.13; P ¼ 0.029) were found to directly correlate
with an increased likelihood of a radiological diagnosis
of HCC (Table 6).
Discussion
Tumor grade has clinical implications in HCC,
because it correlates with well-established predictors of
disease severity and recurrence after surgery, such as
number and size of tumor nodules and portal invasion
by tumor cells.14-18 The present study is the ﬁrst to
evaluate cell grading in small HCC nodules detected
during surveillance of patients with cirrhosis, thus add-
ing to the data regarding cell grading in both small
and large HCC nodules in surgically resected livers. In
our series of early detected tumors, the vast majority
(71%) of the nodules were grade II and III, whereas
none of the tumors was grade IV. The stratiﬁcation of
cell grading in early HCC nodules investigated before
any treatment differs substantially from that reported
in surgical specimens, where the HCC nodules were
greater in size and more dedifferentiated (42%-60%
grade II and III versus 28%-46% grade IV).14,18-22
Although a correlation has been demonstrated between
cell grading and volume of the tumor in surgical stud-
ies,11 such a correlation was not apparent in our study,
which only included HCCs <3 cm. Indeed, the me-
dian volume of tumors we investigated was the same
across all the grading categories (no patient with grade
IV tumors), each volumetric set of HCC (<1 cm, 1-2
cm, >2 cm) containing more grade II and III than
grade I tumors. Although we acknowledge that me-
dium to poorly differentiated HCC nodules can be
more conﬁdently diagnosed by FNB than well-differ-
entiated tumors, our approach of comparing intranod-
ular and extranodular tissue and the yield of liver cores
Table 4. Correlation Between Tumor Size and Rates of
Typical Vascular Pattern (Wash-in Followed by Wash-Out) for
HCC in Contrast Imaging Techniques
Tumor Size
No. Of
Nodules
Wash-In 1 Wash-Out Positives Radiological
Diagnosis
of HCCCE-US CT MRI
0.5-1 cm 3 0 1 1 —
1-2 cm 47 15 21 19* 19
>2 cm 12 6 10 9 10
*Two patients with HCC not investigated with MRI owing to claustrophobia
and a bone metallic plaque, respectively.
Table 5. Rates of Radiological Diagnosis of 1- to 2-cm
Tumors with Single or Dual Imaging Techniques According to
Tumor Cell Grading
Imaging Techniques Grade I Grade II-III
CE-US 3 (19) 12 (39)
CT 3 (19) 18 (58)
MRI 4 (25) 15 (52)*
CE-US þ MRI 1 (6) 6 (21)*
CE-US þ CT 1 (6) 8 (26)
MRI þ CT 2 (13) 11 (38)*
Any dual combination 2 (13) 17 (55)
Data are presented as n (%).
*Two patients with HCC not investigated with MRI owing to claustrophobia
and a bone metallic plaque, respectively.
Table 6. Variables Associated with Radiological Diagnosis of
HCC According to AASLD Criteria
Features
HCC Diagnosed
(n 5 29)
HCC Undiagnosed
(n 5 33) P Value
Male sex 23 (79) 20 (61) 0.11
Age >66 years 11 (41) 18 (55) 0.19
HCV-positive 21 (72) 24 (72) 0.97
Child-Pugh class A 28 (97) 31 (94) 0.63
AFP >100 ng/mL 4 (14) 3 (9) 0.56
Tumor size 1-2 cm 18 (62) 29 (88) 0.035
Tumor grade 1 2 (7) 16 (48) 0.0003
Data are presented as n (%).
Abbreviations: AASLD, American Association for the Study of Liver Diseases;
HCV, hepatitis C virus.
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of adequate length as those obtained with a trenchant
needle, should have reasonably attenuated the risk of
underestimation of tumor grade in our study. The lack
of concordance we demonstrated in 28% of paired
FNB examinations should not have subverted our cor-
relation analysis in small tumors, because only one of
the ﬁve discordant nodules was grade I versus grade II,
whereas the remaining four nodules were discordant
for grade II and III, to give a clinically meaningful dis-
cordance between paired FNB examinations of 5%
only.
A previous study from our group comparing the ac-
curacy of dynamic contrast imaging techniques and
FNB to diagnose HCC in cirrhosis allowed us to
assess whether tumor cell grading had any inﬂuence on
the accuracy of dynamic contrast imaging techniques
that are endorsed for the noninvasive diagnosis of
HCC.9 To maximize the diagnostic accuracy of FNB,
we used a 21-gauge trenchant needle for microhistol-
ogy, resulting in tissue cores of 1.6 cm, on average.
Moreover, by sampling all patients for both nodular
and extranodular liver parenchyma, the differential di-
agnosis between low-grade tumors and dysplastic mac-
roregenerative nodules was eased.23 Finally, to evaluate
the sensitivity of the study, a set of patients underwent
two intranodule biopsies, and the biopsy specimens
were blindly examined by two pathologists who were
unaware of the clinical ﬁndings.
In our study, the diagnostic accuracy of dynamic
contrast imaging techniques appeared to be attenuated
in well-differentiated tumors compared with less differ-
entiated tumors. This may have clinical implications,
because the current standard of care for the radiologi-
cal diagnosis of HCC, represented by the combination
of CE-US and MRI, has been shown to have a sensi-
tivity of 33.3% and a speciﬁcity of 100% in the set-
ting of 0.5- to 2-cm tumors occurring in patients with
cirrhosis.4 Similar ﬁgures were reported by other stud-
ies investigating the combinations of CE-US þ CT
and CT þ MRI in the setting of 1- to 2-cm HCC
nodules.9,24 In the present study, regardless of the dual
combination of dynamic contrast imaging technique
applied, no more than 13% of grade I tumors 2 cm
were correctly identiﬁed on radiological examination,
compared with >50% for grade II and grade III
tumors of similar size. As a consequence, of the 29 ra-
diologically identiﬁed tumors, only 7% were grade I
HCC, which in turn accounted for the 48% of tumors
that were not identiﬁed on radiological examination (P
¼ 0.0003). Altogether, these ﬁndings reinforce the
relationship that exists between arterial vascularization
of the tumor, cell grade, and detectability by dynamic
contrast imaging that was only partially reported by
previous studies.25-29
The fact that in our study multivariate analysis
showed tumor cell grading and nodule size to be the
only two independent predictors of a radiological diag-
nosis of HCC further reinforces the association
between HCC grade and vascularization. The lack of
any correlation between tumor size and cell grading in
our series of small HCC nodules does not contrast
with the well-known correlation between tumor size
and cell grading that has been reported in surgical
HCC nodules. Medium to large tumors are known to
be heterogeneous in cell grading and to be generally
less differentiated than small HCC nodules. We were
not surprised to ﬁnd no correlation between tumor
grade and serum AFP values, because this could reﬂect
the selection of patients with small tumors that rarely
circulate high serum levels of AFP. A correlation
between serum AFP levels and tumor cell grade has
been reported in other clinical settings,30 even though
AFP synthesis in malignant hepatocytes does not
merely reﬂect cell dedifferentiation, but it is a more
complex phenomenon related to HCC heterogeneity.31
Gene expression studies have shown that HCC sub-
groups with consistent AFP overexpression are likely
related to a progenitor cell phenotype with up-regula-
tion of developmental and imprinting genes mainly
occurring in a hepatitis B virus–related background.32
Most of our patients were hepatitis C–related, and it
has also been shown that AFP-negative subgroups are
enriched in HCC with different prognosis (i.e., show-
ing both excellent and poor survival).33
The grade I tumors that we could not classify as
HCC by contrast imaging likely correspond to Barce-
lona Clinic Liver Cancer stage 0 tumors (very early
HCC) originally described in Japan as <2 cm HCCs
having a vaguely nodular appearance and an intact
portal tract–based structure.34,35 In the original report,
all those tumors were grade I and had a favorable out-
come following hepatic resection compared with
tumors of similar size with a distinctly nodular pattern
that were made out by contrast imaging techniques.
The latter tumors were more often dedifferentiated
and tended to recur after hepatic resection.35 The par-
adigm of radiological diagnosis of HCC in cirrhosis
rests on the excess unpaired arteries with respect to
portal vein branches, which accounts for the typical
vascular pattern of wash-in followed by wash-out, a
feature that is expected to be increasingly detected in
parallel with tumor growth. Our ﬁnding of low rates
of contrast wash-in followed by wash-out in grade I
tumors in general, and in particular in those <2 cm,
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speaks in favor of a correlation between tumor cell
grading and arterial vascularization of the tumor, even
though it is unclear which of these variables drives the
prognosis of HCC.11 Furthermore, the fact that small
tumors not identiﬁed by contrast imaging have a be-
nign prognosis ultimately calls for repeat liver biopsy
examinations during the time the nodules remain
unchanged at imaging, because this approach might
help to improve early diagnosis of HCC.
The recent reclassiﬁcation of small HCC, which
resulted from a consensus meeting between eastern
and western pathologists, emphasized the role of tu-
mor grading and vascular remodeling in the classiﬁca-
tion and prognostication of HCC.11 Indeed, the most
differentiated form of very early HCC, which is usu-
ally <2 cm, displays grade I histology and grossly
shows the vaguely nodular architecture mentioned
before, is unlikely to inﬁltrate the portal vein system
and to disseminate into the liver. Interestingly enough,
this tumor is characterized by an incomplete neovascu-
larization, whereby it often escapes detection by con-
trast imaging.2 Conversely, the small but more aggres-
sive early HCC is characterized by a gross nodular
architecture, a less differentiated histology, and a com-
plete and extensive arterial neovascularization. The lat-
ter, unlike very early HCC, has a less favorable prog-
nosis, because it is able to inﬁltrate the portal vein
system and to disseminate into the liver in 27% and
10% of cases, respectively.8
In conclusion, our study indicates that the accuracy
of dynamic contrast imaging techniques to diagnose
early HCC in cirrhosis is largely affected not only by
the degree of arterial vascularization but also by cell
grading of the nodule. Although this observation
speaks in favor of a better prognosis for these nodules
compared with those readily identiﬁed by radiological
analysis, it further endorses the need for the histologi-
cal examination of all small nodules arising in cirrhotic
livers that are left undiagnosed by radiology.
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